About
Epigenomics AG is a molecular diagnostics company founded in 1998 and based in Berlin, Germany, with a subsidiary in Seattle, Washington. The company is publicly traded on the Frankfurt Stock Exchange under the ticker ECX. Epigenomics specializes in developing and commercializing minimally invasive diagnostic tests for oncology, focusing on DNA methylation-based biomarkers that aid in the detection and diagnosis of various cancers. Key products include Epi proColon, a blood-based test for early colorectal cancer detection, and Epi proLung, which assists in lung cancer diagnosis. The company also works on the PITX2 biomarker for prostate cancer prognosis. Epigenomics aims to make methylation testing routine in clinical laboratories and has contributed significantly to biomarker science, with over 60 peer-reviewed publications in the last decade. Its target customers include healthcare providers, clinical laboratories, and oncology specialists in Europe and North America.
Technologies
Keywords
Company Information
- Employees33
- Founded1998
- Annual Revenue$7055000
- Total Funding$110133450
Location
11055 Flintkote Ave, San Diego, California, United States, 92121
